DMAC Stock Analysis: Buy, Sell, or Hold?
DMAC - DiaMedica Therapeutics Inc. Common Stock
$5.65
-0.12 (-2.08%)
▼
5d:
-7.38%
30d:
-6.61%
90d:
-27.28%
HOLD
LOW Confidence
Analysis Updated: Jun 3, 2026 12:00 AM ET
Earnings: May 19, 2026
0d
Get Alerted When DMAC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: DMAC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: DMAC shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: DMAC is currently trading at $5.65, which is considered oversold relative to its 30-day fair value range of $5.82 to $6.36.
Technical Outlook: Technically, DMAC is in a strong downtrend. The price is currently testing key support at $5.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DMAC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.50 (+174.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, DMAC is in a strong downtrend. The price is currently testing key support at $5.50. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: DMAC has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $15.50 (+174.3%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.82 -
$6.36
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 174.3% below Wall St target ($15.50)
- CAUTION: Recommendation downgraded due to -7.4% 5-day decline
Trading Range Analysis
30-Day Trading Range
$5.82 -
$6.36
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$0.86
(15.1%)
Support & Resistance Levels
Support Level
$5.50
Resistance Level
$6.45
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.42
Wall Street Target
$15.50
(+174.3%)
Share & Embed Analysis
Last updated: June 03, 2026 7:47 PM ET
Data refreshes hourly during market hours. Next update: 8:47 PM
Data refreshes hourly during market hours. Next update: 8:47 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DMAC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 54 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 55 HOLD |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 62 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 56 HOLD |
